Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
C$10.60
-3.8%		C$10.60
C$3.50
▼
C$15.75
C$168.68MN/A12,671 shs3,402 shs
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
C$4.06
-0.2%		C$3.23
C$1.55
▼
C$4.59
C$112.13M0.93904116,398 shs108 shs
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
$25.07
-0.4%		$25.71
$24.91
▼
$26.72
$2.76B0.281.16 million shs180,466 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
▼
$8.75
$644.67M0.76N/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00%0.00%0.00%0.00%0.00%
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
+2.52%+0.49%+23.33%+98.54%+102.49%
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
-0.16%-0.16%-2.02%-3.64%-4.84%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
C$10.60
-3.8%		C$10.60
C$3.50
▼
C$15.75
C$168.68MN/A12,671 shs3,402 shs
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
C$4.06
-0.2%		C$3.23
C$1.55
▼
C$4.59
C$112.13M0.93904116,398 shs108 shs
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
$25.07
-0.4%		$25.71
$24.91
▼
$26.72
$2.76B0.281.16 million shs180,466 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
▼
$8.75
$644.67M0.76N/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00%0.00%0.00%0.00%0.00%
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
+2.52%+0.49%+23.33%+98.54%+102.49%
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
-0.16%-0.16%-2.02%-3.64%-4.84%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00
N/AN/AN/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
0.00
N/AN/AN/A
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
0.00
N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3.00
Buy$1.00-84.54% Downside

Current Analyst Ratings Breakdown

Latest SVA, BCT, COV, and SCYB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$6.00 ➝ $1.00
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AC$3.34 per share3.17C$3.60 per shareN/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
C$34.35M3.26C$0.95 per share4.28C$1.14 per share3.55
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/AN/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$386.01M1.67$0.54 per share11.89$89.01 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A-C$0.38N/AN/AN/AN/AN/AN/AN/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
C$2.39MC$0.1625.38N/AN/A12.78%15.04%-3.25%N/A
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/AN/A60.28N/AN/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$59.68MN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
N/AN/AN/AN/AN/A
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
$1.807.18%N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.05
129.63
128.68
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
5.35
8.56
6.45
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.04
6.07
5.97

Institutional Ownership

CompanyInstitutional Ownership
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
0.16%
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A

Insider Ownership

CompanyInsider Ownership
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
48.70%
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
12.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
515.91 millionN/ANot Optionable
Covalon Technologies Ltd. stock logo
COV
Covalon Technologies
10527.62 millionN/ANot Optionable
Schwab High Yield Bond ETF stock logo
SCYB
Schwab High Yield Bond ETF
N/A110.30 millionN/ANot Optionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,00899.64 million86.89 millionOptionable

Recent News About These Companies

Sernova, Seraxis Aim for Type 1 Diabetes ‘Functional Cure’ With BetaNova Merger
October 4, 2026  |  defenseworld.netD
Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA
July 21, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SVA/events
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
July 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260710642585/en/sinovac-announces-extension-of-deadline-to-submit-payment-instructions-for-previously-declared-special-cash-dividend/
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
July 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20250615436271/en/SINOVAC-Board-of-Directors-Alerts-Shareholders-to-AdvantechPrime-Success-New-Lawsuit-Which-Threatens-to-Prevent-Payment-of-US%2455.00-Special-Dividend-to-All-Valid-Shareholders
Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sinovac-regains-nasdaq-listing-compliance-after-filing-delayed-annual-report?utm_source=marketbeat.com&utm_medium=referral
Sinovac Biotech Ltd.
June 8, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/SVA
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
June 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260604567485/en/SINOVAC-Reports-Unaudited-and-Unreviewed-Second-Half-of-2025-Financial-Results-and-Files-2025-Annual-Report-on-Form-20-F/
Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sinovac-faces-new-nasdaq-delisting-risk-after-regaining-compliance?utm_source=marketbeat.com&utm_medium=referral
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
May 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260529895816/en/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-annual-report/
SVA Share News Today
May 16, 2026  |  uk.investing.comhttps://uk.investing.com/equities/sinovac-biotech-news/2
SINOVAC Reports Unaudited First Half of 2025 Financial Results
May 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260508098846/en/SINOVAC-Reports-Unaudited-First-Half-of-2025-Financial-Results/
Sinovac Biotech Delays Key Annual 20-F Filing
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sinovac-biotech-delays-key-annual-20-f-filing?utm_source=marketbeat.com&utm_medium=referral
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
April 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260429934070/en/sinovac-files-annual-report-on-form-20-f-for-the-fiscal-year-2024/
Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.
March 28, 2026  |  tennessean.comT
Sinovac Controlling Shareholders Escape Investor Disclosure Suit
February 25, 2026  |  news.bloomberglaw.comN
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
January 22, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260122376718/en/sinovac-announces-nasdaq-hearings-panel-grants-continued-listing/
Sinovac Biotech receives Nasdaq notification regarding late filing of FY25
January 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/sinovac-biotech-receives-nasdaq-notification-regarding-late-filing-of-fy25/ar-AA1TyUWG
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
January 4, 2026  |  financialpost.comF
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
January 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260104122574/en/sinovac-provides-update-on-antigua-high-court-order-and-auditor-engagement/
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
January 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260104600593/en/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Glass-walled office building lobby at sunset with a city skyline reflected in the exterior facade.
Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
By Chris Markoch | September 27, 2026
Lennar logo overlaid on a residential neighborhood with completed homes and houses under construction at sunset.
Lennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
By Thomas Hughes | September 18, 2026
Rows of used vehicles parked in a lot outside a CarMax dealership building with its logo displayed.
CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
By Thomas Hughes | September 29, 2026
A laptop displaying an upward-trending multi-line stock chart sits on a wooden desk beside a coffee mug and smartphone.
MarketBeat Week in Review – 09/14 - 09/18
By MarketBeat Staff | September 19, 2026
A glass cube engraved with "ETF" sits on a wooden desk in a modern office setting.
3 Zero-Fee ETFs Worth More Than Their Cost
By Nathan Reiff | September 18, 2026
BriaCell Therapeutics stock logo

BriaCell Therapeutics CVE:BCT

C$10.60 -0.42 (-3.81%)
As of 12/30/2021

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Covalon Technologies stock logo

Covalon Technologies CVE:COV

C$4.06 -0.01 (-0.25%)
As of 09:30 AM Eastern

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

Schwab High Yield Bond ETF stock logo

Schwab High Yield Bond ETF NYSEARCA:SCYB

$25.06 -0.11 (-0.42%)
As of 10:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)
As of 10/13/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas